GlobeNewswire Clinical StudiesOriginal article
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Phase 3HLP003Positive
AI Analysis
Summary
Helus Pharma completed enrollment in the Phase 3 APPROACH study of HLP003 for adjunctive treatment of major depressive disorder ahead of schedule. The company continues enrollment in EMBRACE, a second pivotal Phase 3 study under the PARADIGM Program.
Clinical Trial Data
Phase
Phase 3
Outcome Details
APPROACH study enrollment completed ahead of schedule
Importance:6/10
Sentiment:
0.70
Phase 3Major Depressive Disorderenrollment completionPARADIGM ProgramAPPROACH studyEMBRACE study
Read the original article
Published by GlobeNewswire Clinical Studies on July 21, 2026 11:50 AM